Efficacy and safety evaluation of fixed dose combination of Cefepime and Amikacin in comparison with Cefepime alone in treatment of nosocomial pneumonia patients

Current Clinical Pharmacology

Volumn 3, Issue 2, 2008, Pages 118-122

  Chaudhary, Manu ^a   Shrivastava, Sanjay Mohan ^a   Varughese, Lallu ^a   Sehgal, Rajesh ^a  

^a Venus Remedies Limited   (India)

Author keywords

Amikacin; Cefepime; Nosocomial pneumonia; P. aeruginosa; Synergistic

Indexed keywords

AMIKACIN PLUS CEFEPIME; ANTIBIOTIC AGENT; CEFEPIME; UNCLASSIFIED DRUG; AMIKACIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER; ADULT; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; REVIEW; STAPHYLOCOCCUS AUREUS; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ARTICLE; COMPARATIVE STUDY; CROSS INFECTION; DRUG COMBINATION; GRAM NEGATIVE INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMIKACIN; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CROSS INFECTION; DRUG COMBINATIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 52049123169     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408784293660     Document Type: Review

References (18)

1. Hoffken G, Niederman MS. Nosocomial pneumonia: The importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122(6): 2183-96.
2. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274(8): 639-44.
3. Chastre J. Antimicrobial treatment of hospital-acquired pneumonia. Infect Dis Clin North Am 2003; 17(4): 727-37.
4. Ibrahim EH, Tracy L, Hill C, Fraser VJ, Kollef MH. The occurrence of ventilator-associated pneumonia in a community hospital: risk factors and clinical outcomes. Chest 2001; 120(2): 555-61.
5. Diaz E, Munoz E, Agbaht K, Rello J. Management of ventilator-associated pneumonia caused by multiresistant bacteria. Curr Opin Crit Care 2007; 13(1): 45-50.
6. Shorr AF, Kollef MH. Ventilator-associated pneumonia: insights from recent clinical trials. Chest 2005; 128: 583S-591S.
7. Tumah H. Fourth-generation Cephalosporins: In vitro activity against nosocomial gram- negative bacilli compared with betalactam antibiotics and ciprofloxacin. Chemotherapy 2005; 51(2-3): 80-5.
8. Sanz MA, Lopez J, Lahuerta JJ, et al. Cefepime plus Amikacin versus Piperacillin-Tazobactam plus Amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002; 50(1): 79-88.
9. Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 2005; 51(5): 227-33.
10. Beaucaire G, Nicolas MH, Martin C, et al. [Phare study. Comparative study of combined Cefepime-Amikacin versus Ceftazidime combined with Amikacin in the treatment of nosocomial pneumonias in ventilated patients]. Multicenter group study. Ann Fr Anesth Reanim 1999; 18(2): 186-95.
11. Roberts JA, Webb SA, Lipman J. Cefepime versus Ceftazidime: considerations for empirical use in critically ill patients. Int J Antimicrob Agents 2007; 29(2): 117-28.
12. Alvarez-Lerma F, Insausti-Ordeñana J, Jordá-Marcos R, et al. Efficacy and tolerability of piperacillin/tazobactam versus Ceftazidime in association with Amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27(3): 493-502.
13. Gouin F, Papazian L, Martin C, et al. A non-comparative study of the efficacy and tolerance of Cefepime in combination with Amikacin in the treatment of severe infections in patients in intensive care. J Antimicrob Chemother 1993; 32(Suppl B): 205-14.
14. Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med 2003; 2(1): 75-107.
15. Angelescu M, Apostol A. Cefepime (maxipime), large spectrum 4th generation Cephalosporin, resistant to beta-lactamases. Chirurgia (Bucur) 2001; 96(6): 547-52.
16. Mimoz O, Jacolot A, Padoin C, Tod M, Samii K, Petitjean O. Cefepime and Amikacin synergy in vitro and in vivoagainst a Ceftazidime-resistant strain of Enterobacter cloacae. J Antimicrob Chemother 1998; 41(3): 367-72.
17. Dubois V, Arpin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of Cefepime-Amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol 2001; 39(6): 2072-78.
18. Cunha BA. Nosocomial pneumonia. Diagnostic and therapeutic considerations. Med Clin North Am 2001; 85(1): 79-114.